Zymeworks (ZYME) Stock Price, News & Analysis

Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $13.03 to $13.58
• 50-Day Range: N/A
• 52-Week Range: $9.03 to $17.70
• Volume: 357,410 shs
• Average Volume: 384,689 shs
• Market Capitalization: $941.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZYME Stock Analysis - Frequently Asked Questions

How have ZYME shares performed this year?

Zymeworks' stock was trading at $13.33 at the beginning of 2025. Since then, ZYME stock has increased by 1.4% and is now trading at $13.51.

When did Zymeworks IPO?

Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZYME
• Previous Symbol: NASDAQ:ZYME
• CIK: 1937653
• Web: N/A
• Phone: (302) 274-8744
• Fax: 604-737-7077
• Employees: 460
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$122.69 million
• Net Margins: -121.73%
• Pretax Margin: -114.77%
• Return on Equity: -26.83%
• Return on Assets: -20.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.71
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $76.30 million
• Price / Sales: 12.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.92 per share
• Price / Book: 2.75

Miscellaneous

• Outstanding Shares: 69,680,000
• Free Float: 68,345,000
• Market Cap: $941.38 million
• Optionable: N/A
• Beta: 1.19